The association between calcium dobesilate and pancytopenia in type 2 diabetes: A case report

Kaynakça (6)

1. Lionis C, Erevnidou K, Antonakis N, Argyriadou S, Vlachonikolis I, Katsamouris A; CVI Research Group. Chronic venous insufficiency. A common health prob- lem in general practice. Int Angiol 2002;21:86-92.
2. Fowkes FGR, Ewans CJ, Lee AJ. Prevalance and risk factors of chronic venous insufficiency. Angiology 2001;52:S5-15. [CrossRef] Allain H, Ramelet AA, Polard E, Bentue-Ferrer D. Safety of calcium dobesilate in chronic venous disease, dia- betic retinopathy and haemorrhoids. Drug Saf. 2004;27:649-60. [CrossRef] Zapater P Horga JF, Garcia A. Risk of drug-induced agranulocytosis: the case of calcium dobesilate. Eur J Clin Pharmacol. 2003;58:767-72.
3. Ibanez L, Ballarin E, Vidal X, Laporte JR. Agranulocytosis associated with calcium dobesilate clinical course and risk estimation with the case-control and the case- population approaches. Eur J Clin Pharmacol. 2000;56:763-7.
4. Kulessa W, Becker EW, Berg PA. Recurrent agranulocy- tosis after taking calcium dobesilate. Dtsch Med Wochenschr. 1992;117:372-4. [CrossRef] Garcia Benayas E, Garcia Diaz B, Perez G. Calcium dobesilate-induced agranulocytosis. Pharm World Sci. 1997;19:251-2. [CrossRef] Azaceta G, Sáenz-Cusi A, Olave T, Palomera L. Agranulocitosis inducida por dobesilato cálcico: a propósito de un nuevo caso. An Med Interna 2000;17: 337-8.
5. Duggal L, Thukral R, Kumar S. Calcium dobesilate- induced agranulocytosis. J Assoc Physicians India. 2005;53:320-1.
6. Ibanez L, Vidal X, Ballarin E, Laporte JR. Population- based drug-induced agranulocytosis. Arch Intern Med. 2005;165:869-74. [CrossRef]